20/20 Biolabs Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.8M
- Price
- $0.5543
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.82%
- Volume
- 230.9K
About
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Quick stats
Shares outstanding12.3M
Computed float10.2M
Float / shares83.0%
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001139685
Websitehttps://2020biolabs.com
AI Summary
AI-generated1/29
minorbullishoperations update
HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences Innovation
HEALWELL AI announced that its subsidiary Pentavere Research Group has been nominated for the 2026 International Prix Galien Award in the Best Startup category for its DARWEN AI platform.
This nomination advances Pentavere from its 2024 Prix Galien USA Award win to the global stage, placing it among nominees from major pharmaceutical and medical technology companies like Pfizer and Merck.
Management views the recognition as significant independent validation of the platform's scientific foundation and its strategic value within HEALWELL's broader healthcare ecosystem.